Abstract
We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / genetics*
-
Carcinoma, Renal Cell / mortality
-
Cell Nucleus / metabolism
-
Cell Proliferation
-
Cyclin-Dependent Kinase Inhibitor p27 / genetics
-
DNA-Binding Proteins / genetics*
-
DNA-Binding Proteins / metabolism
-
Enhancer Elements, Genetic*
-
Enhancer of Zeste Homolog 2 Protein
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / genetics*
-
Kidney Neoplasms / mortality
-
Male
-
MicroRNAs / genetics
-
MicroRNAs / metabolism*
-
Middle Aged
-
Polycomb Repressive Complex 2
-
RNA Interference
-
Transcription Factors / genetics*
-
Transcription Factors / metabolism
-
Tumor Cells, Cultured
Substances
-
Biomarkers, Tumor
-
DNA-Binding Proteins
-
MIRN101 microRNA, human
-
MicroRNAs
-
Transcription Factors
-
Cyclin-Dependent Kinase Inhibitor p27
-
EZH2 protein, human
-
Enhancer of Zeste Homolog 2 Protein
-
Polycomb Repressive Complex 2